Fructosamine 3-kinase and glyoxalase I polymorphisms and their association with soluble RAGE and adhesion molecules in diabetes

Physiological Research

Volumn 63, Issue SUPPL.2, 2014, Pages

  Skrha Jr J ^a   Muravska A ^a   Flekac M ^a   Horova E ^a   Novak J ^a   Novotny A ^a   Prazny M ^a   Skrha J ^a   Kvasnicka J ^a   Landova L ^a   Jachymova M ^a   Zima, T ^a   Kalousova M ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Adhesion molecules; Diabetes; Fructosamine 3 kinase; Glyoxalase I; SRAGE

Indexed keywords

ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; BIOLOGICAL MARKER; CELL ADHESION MOLECULE; FRUCTOSAMINE-3-KINASE; IMMUNOGLOBULIN RECEPTOR; LACTOYLGLUTATHIONE LYASE; PHOSPHOTRANSFERASE;

ADOLESCENT; ADULT; AGED; BLOOD; CASE CONTROL STUDY; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; ENZYMOLOGY; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; HUMAN; MALE; MIDDLE AGED; PHENOTYPE; RISK FACTOR; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CELL ADHESION MOLECULES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LACTOYLGLUTATHIONE LYASE; MALE; MIDDLE AGED; PHENOTYPE; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); POLYMORPHISM, GENETIC; RECEPTORS, IMMUNOLOGIC; RISK FACTORS; YOUNG ADULT;

EID: 84903787124     PISSN: 08628408     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. ALLEN RE, LO TWC, THORNALLEY PJ: A simplified method for the purification of human red-blood-cell glyoxalase. I. Characteristics, immunoblotting, and inhibitor studies. J Prot Chem 12: 111-119, 1993.
2. BARUA M, JENKINS EC, CHEN WQ, KUIZON S, PULLARKAT RK, JUNAID MA: Glyoxalase I polymorphism rs2736654 causing the Ala111Glu substitution modulates enzyme activity-implications for autism. Autism Res 4: 262-270, 2011.
3. BROWNLEE M: The pathobiology of diabetic complications - a unifying mechanism. Diabetes 54: 1615-1625, 2005.
4. CAI WJ, RAMDAS M, ZHU L, CHEN X, STRIKER GE, VLASSARA H: Oral advanced glycation endproducts (AGEs) promote insulin resistance and diabetes by depleting the antioxidant defenses AGE receptor-1 and sirtuin 1. Proc Nat Acad Sci USA 109: 15888-15893, 2012.
5. DAFFU G, DEL POZO CH, O'SHEA KM, ANANTHAKRISHNAN R, RAMASAMY R, SCHMIDT AM: Radical roles for RAGE in the pathogenesis of oxidative stress in cardiovascular diseases and beyond. Int J Mol Sci 14: 19891-19910, 2013.
6. DELPIERRE G, VAN SCHAFTINGEN E: Fructosamine 3-kinase, an enzyme involved in protein deglycation. Biochem Soc Trans 31: 1354-1357, 2003.
7. DELPIERRE G, VEIGA-DA-CUNHA M, VERTOMMEN D, BUYSSCHAERT M, VAN SCHAFTINGEN E: Variability in erythrocyte fructosamine 3-kinase activity in humans correlates with polymorphisms in the FN3K gene and impacts on haemoglobin glycation at specific sites. Diabetes Metab 32: 31-39, 2006.
8. EL-MESALLAMY HO, HAMDY NM, EZZAT OA, REDA AM: Levels of soluble advanced glycation end productreceptors and other soluble serum markers as indicators of diabetic neuropathy in the foot. J Invest Med 59: 1233-1238, 2011.
9. ENGELEN L, FERREIRA I, BROUWERS O, HENRY RMA, DEKKER JM, NIJPELS G, HEINE RJ, VAN GREEVENBROEK MMJ, VAN DER KALLEN CJH, BLAAK EE, FESKENS EJM, TEN CATE H, Stehouwer Cda, Schalkwijk Cg: Polymorphisms In Glyoxalase 1 Gene Are Not Associated With Vascular complications: the Hoorn and CoDAM studies. J Hypertens 27: 1399-1403, 2009.
10. GENUTH S, SUN WJ, CLEARY P, SELL DR, DAHMS W, MALONE J, SIVITZ W, MONNIER VM, ANCILLARY DSC: Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes. Diabetes 54: 3103-3111, 2005.
11. GERMANOVA A, TESAROVA P, JACHYMOVA M, ZVARA K, ZIMA T, KALOUSOVA M: Glyoxalase I Glu111Ala polymorphism in patients with breast cancer. Cancer Invest 27: 655-660, 2009.
12. GIACCO F, DU X, D'AGATI VD, MILNE R, SUI G, GEOFFRION M, BROWNLEE M: Knockdown of glyoxalase 1 mimics diabetic nephropathy in nondiabetic mice. Diabetes 63: 291-299, 2014.
13. KALOUSOVA M, HODKOVA M, KAZDEROVA M, FIALOVA J, TESAR V, DUSILOVA-SULKOVA S, ZIMA T: Soluble receptor for advanced glycation end products in patients with decreased renal function. Am J Kidney Dis 47: 406-411, 2006.
14. KALOUSOVA M, JACHYMOVA M, MESTEK O, HODKOVA M, KAZDEROVA M, TESAR V, ZIMA T: Receptor for advanced glycation end products - soluble form and gene polymorphisms in chronic haemodialysis patients. Nephrol Dial Transplant 22: 2020-2026, 2007.
15. KALOUSOVA M, GERMANOVA A, JACHYMOVA M, MESTEK O, TESAK V, ZIMA T: A419C (E111A) polymorphism of the glyoxalase I gene and vascular complications in chronic hemodialysis patients. Ann NY Acad Sci 1126: 268-271, 2008.
16. KUSUNOKI H, MIYATA S, OHARA T, LIU BF, URIUHARA A, KOJIMA H, SUZUKI K, MIYAZAKI H, YAMASHITA Y, INABA K, KASUGA M: Relation between serum 3-deoxyglucosone and development of diabetic microangiopathy. Diabetes Care 26: 1889-1894, 2003.
17. LEVEY AS, BOSCH JP, LEWIS JB, GREENE T, ROGERS N, ROTH D: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130: 461-470, 1999.
18. LINDSEY JB, CIPOLLONE F, ABDULLAH SM, MCGUIRE DK: Receptor for advanced glycation end-products (RAGE) and soluble RAGE (sRAGE): cardiovascular implications. Diabetes Vasc Dis Res 6: 7-14, 2009.
19. MIYATA T, DE STRIHOU CV, IMASAWA T, YOSHINO A, UEDA Y, OGURA H, KOMINAMI K, ONOGI H, INAGI R, NANGAKU M, KUROKAWA K: Glyoxalase I deficiency is associated with an unusual level of advanced glycation end products in a hemodialysis patient. Kidney Int 60: 2351-2359, 2001.
20. MOHAS M, KISFALI P, BARICZA E, MEREI A, MAASZ A, CSEH J, MIKOLAS E, SZIJARTO IA, MELEGH B, WITTMANN I: A polymorphism within the fructosamine-3-kinase gene is associated with HbA(1c) levels and the onset of type 2 diabetes mellitus. Exp Clin Endocrinol Diab 118: 209-212, 2010.
21. MOSCA L, PENCO S, PATROSSO MC, MAROCCHI A, LAPOLLA A, SARTORE G, CHILELLI NC, PALEARI R, Mosca A: Genetic Variability Of The Fructosamine 3-Kinase Gene In Diabetic Patients. Clin Chem Lab Med 49: 803-808, 2011.
22. PIARULLI F, LAPOLLA A, RAGAZZI E, SUSANA A, SECHI A, NOLLINO L, COSMA C, FEDELE D, SARTORE G: Role of endogenous secretory RAGE (esRAGE) in defending against plaque formation induced by oxidative stress in type 2 diabetic patients. Atherosclerosis 226: 252-257, 2013.
23. POPOVA EA, MIRONOVA RS, ODJAKOVA MK: Non-enzymatic glycosylation and deglycating enzymes. Biotechnol Biotec Eq 24: 1928-1935, 2010.
24. RABBANI N, THORNALLEY PJ: Glyoxalase in diabetes, obesity and related disorders. Semin Cell Dev Biol 22: 309-317, 2011.
25. ROBERTS AC, PORTER KE: Cellular and molecular mechanisms of endothelial dysfunction in diabetes. Diab Vasc Dis Res 10: 472-482, 2013.
26. SANTILLI F, BUCCIARELLI L, NOTO D, CEFALU AB, DAVI V, FERRANTE E, PETTINELLA C, AVERNA MR, CIABATTONI G, DAVI G: Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins. Free Radic Biol Med 43: 1255-1262, 2007.
27. SELVIN E, HALUSHKA MK, RAWLINGS AM, HOOGEVEEN RC, BALLANTYNE CM, CORESH J, ASTOR BC: sRAGE and risk of diabetes, cardiovascular disease, and death. Diabetes 62: 2116-2121, 2013.
28. SILVA MS, GOMES RA, FERREIRA AEN, FREIRE AP, CORDEIRO C: The glyoxalase pathway: the first hundred years. and beyond. Biochem J 453: 1-15, 2013.
29. SKRHA J JR, KALOUSOVA M, SVARCOVA J, MURAVSKA A, KVASNICKA J, LANDOVA L, ZIMA T, SKRHA J: Relationship of soluble RAGE and RAGE ligands HMGB1 and EN-RAGE to endothelial dysfunction in type 1 and type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 120: 277-281, 2012.
30. SONG F, SCHMIDT AM: Glycation and insulin resistance: novel mechanisms and unique targets? Arterioscler Thromb Vasc Biol 32: 1760-1765, 2012.
31. Tanhäuserová V, Kuricová K, Pácal L, BartáKová V, Rehorová J, Svojanovskỳ J, Olšovskỳ J, Belobrádková J, KankovÁ K: Genetic variability in enzymes of metabolic pathways conferring protection against non-enzymatic glycation versus diabetes-related morbidity and mortality. Clin Chem Lab Med 52: 77-83, 2014.
32. UGURLU N, GERCEKER S, YULEK F, UGURLU B, SARI C, BARAN P, CAGIL N: The levels of the circulating cellular adhesion molecules ICAM-1, VCAM-1 and endothelin-1 and the flow-mediated vasodilatation values in patients with type 1 diabetes mellitus with early-stage diabetic retinopathy. Intern Med 52: 2173-2178, 2013.
33. URSO C, CAIMI G: Oxidative stress and endothelial dysfunction. Minerva Medica 102: 59-77, 2011.
34. VLASSARA H, STRIKER GE: Advanced glycation endproducts in diabetes and diabetic complications. Endocrin Metab Clin 42: 697-719, 2013.
35. WILLIAMS R, LIM JE, HARR B, WANG C, WALTERS R, DISTLER MG, TESCHKE M, WU CL, WILTSHIRE T, SU AI, SOKOLOFF G, TARANTINO LM, BOREVITZ JO, PALMER AA: A common and unstable copy number variant is associated with differences in Glo1 expression and anxiety-like behavior. Plos One 4: article number e4649, 2009
36. YAN SF, D'AGATI V, SCHMIDT AM, RAMASAMY R: Receptor for Advanced Glycation Endproducts (RAGE): a formidable force in the pathogenesis of the cardiovascular complications of diabetes & aging. Curr Mol Med 7: 699-710, 2007.
37. YONEKURA H, YAMAMOTO Y, SAKURAI S, PETROVA RG, ABEDIN MJ, LI H, YASUI K, TAKEUCHI M, MAKITA Z, TAKASAWA S, OKAMOTO H, WATANABE T, YAMAMOTO H: Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 370: 1097-1109, 2003.
38. ZIEMAN SJ, MELENOVSKY V, CLATTENBURG L, CORRETTI MC, CAPRIOTTI A, GERSTENBLITH G, KASS DA: Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension. J Hypertens 25: 577-583, 2007.